RNAi Therapeutics and Technology Market Revenue to Cross USD 9.1 Billion by 2035 | Roots Analysis

Published: February 2024


According to a recently published report by Roots Analysis, the growing preferences for precision medicine and target-specific therapies have increased the demand for RNAi therapeutics and technology.

Global RNAi Therapeutics and Technology Market Overview

The global RNA therapeutics and technology market is anticipated to grow at a CAGR of 15.4% from 2023-2035, reaching USD 9.1 billion by 2035.

RNAi therapeutics refers to the novel class of innovative drugs that harness the RNA interference (RNAi) property of genes for the regulation of the expression system naturally inside the cells. In the past few years, RNAi therapies have garnered significant attention owing to their ability to treat a broad array of diseases, including metabolic diseases, chronic diseases, and cancer. It is interesting to note here that, in 2018, ONPATTRO® became the first RNAi-based therapy to receive approval from the FDA to treat patients suffering from chronic diseases. Since then, three consecutive RNAi-based therapies, namely, GIVLAARI® (November 2019), LEQVIO® (October 2020), and OXLUMO™ (November 2020), have received approval from the FDA. Notably, more than 200 RNAi therapeutics are currently being evaluated across different clinical trials for the treatment of a broad array of disease indications. Currently, several industrial players are increasing their research efforts for the development of RNA interference technology, aiming to enhance efficacy and reduce effector molecule concentrations based on the anti-sense approach. Driven by the ongoing research, it is estimated that the market will grow during the forecast period.

The 421-page report contains a detailed Table of Contents on "RNAi Therapeutic and Technology Market," Key Therapeutic Areas, Route of Administration, Leading Industry Players, Type of RNAi Molecule and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/rnai-therapeutics-market/278.html

Market Drivers

RNAi technology enables the development of precision medicine by selectively silencing specific genes associated with particular diseases. Further, RNAi technology also holds significant potential in the treatment of genetic disorders owing to its ability to modulate the disease-causing gene. The RNAi therapeutic and technology market is further driven by the ongoing research on this gene silencing mechanism as an essential tool for the treatment of cancer. The growing usage of RNAi technology in the development of antiviral therapies becomes a major driver propelling the growth in the RNAi therapeutic and technology market.

Market Restraints

Delivery challenges and off-target effects are the major market restraints that impede its growth. The introduction of RNA molecules to particular cells may trigger an immune response that can reduce the effectiveness of the RNAi therapeutics. Furthermore, large-scale production of RNAi therapeutics can be challenging for companies. Navigating the complex regulatory pathway to demonstrate the safety and efficacy of RNAi therapeutics can be difficult for companies.

Growth Factors

The ongoing progress of RNAi therapeutics in clinical trials and rising approval from the regulatory authorities are the key growth factors driving the market. Researchers in this field are continually exploring the new therapeutic applications of RNAi technology beyond conventional therapeutics to treat a broad range of diseases. Additionally, the ongoing advancement in the delivery system to enhance the therapeutic efficiency of RNAi therapeutics has become another essential growth factor that will drive the market in the future.

RNAi Therapeutics and Technology Market Segments

Based on the Target Therapeutics Areas, The RNAi Therapeutics and Technology Market is Segmented into Oncological Disorders, Genetic Disorders, Metabolic Disorders, Hematological Disorders, Ophthalmic Disorders and Other Disorders.

  • Based on the target therapeutics areas, the market is dominated by metabolic disorders, capturing 32% of the revenue share by 2035.
  • Oncological disorders will grow during the forecast period at a higher CAGR of 36%.

Based on the Route of Administration, the RNAi Therapeutics and Technology Market is Segmented into Subcutaneous, Intravenous, Topical and Intradermal.

  • Based on the route of administration, the RNAi Therapeutics and Technology market is dominated by subcutaneous routes and is estimated to capture 83% by 2035.
  • Intradermal route of administration will grow at a higher CAGR of 36% during the forecast period.

Based on the Leading Industrial Players, the RNAi Therapeutics and Technology Market is Captured by AgelessRx, Alnylam Pharmaceuticals, ANOVA Institute for Regenerative Medicine, Betterhumans, BioAge Labs, bioXcellerator, Cambrian Biopharma, Gero.ai, Gradalis, Mayo Clinic, Rejuvenate Bio and UT Health San Antonio.

  • Alnylam Pharmaceuticals will dominate the market, capturing a significant share of (58%) by 2035.
  • Gradalis will grow during the forecast period at a CAGR of 36%.

Based on the Type of RNAi Molecules, the RNAi Therapeutics and Technology Market is Segmented into siRNA and shRNA.

  • SiRNA will dominate the RNAi therapeutics and technology market, capturing 99.8% of the overall revenue share by 2035. 
  • ShRNA will grow at a higher compounded annual growth rate (CAGR) of 36% during the forecast period.

Based on the Key Geographical Region, the RNAi Therapeutics and Technology Market is Segmented into North America, Europe, Asia-Pacific and Rest of the World.

  • North America will dominate the market and is poised to capture 81% of the overall revenue share by 2035.
  • In Europe, the RNAi therapeutics and technology market will grow during the forecast period at a CAGR of 16%.

Key Companies Profiled

The RNAi therapeutics and technology market report also includes detailed profiles of key players (listed below) that offer biosensor solutions for drug discovery.

  • AgelessRx
  • ANOVA Institute for Regenerative Medicine
  • Betterhumans
  • BioAge Labs
  • BioXcellerator
  • Cambrian Biopharma
  • Gero.ai
  • Mayo Clinic
  • Rejuvenate Bio
  • UT Health San Antonio

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/rnai-therapeutics-market-2nd-edition-2019-2030/request-sample.html

Don’t Miss Out on Other Interesting Titles:

  1. Genome Editing Market
  2. RNA Therapeutics and RNA Vaccines Market
  3. Next Generation Drug Conjugates Market

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact US
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry